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Abstract
Personalized therapies are required for Fabry disease due to its large phenotypic spectrum
and numerous different genotypes. In principle, missense mutations that do not affect the
active site could be rescued with pharmacological chaperones. At present pharmacological
chaperones for Fabry disease bind the active site and couple a stabilizing effect, which is
required, to an inhibitory effect, which is deleterious. By in silico docking we identified an
allosteric hot-spot for ligand binding where a drug-like compound, 2,6-dithiopurine, binds
preferentially. 2,6-dithiopurine stabilizes lysosomal alpha-galactosidase in vitro and res-
cues a mutant that is not responsive to a mono-therapy with previously described pharma-
cological chaperones, 1-deoxygalactonojirimycin and galactose in a cell based assay.
Introduction
Fabry disease (FD) is a rare pathology, but accounts for 8.8% of the patients affected by inher-
ited disorders of metabolism [1]. It is caused by mutations in the gene GLA, which is located
on the X chromosome and encodes lysosomal alpha-galactosidase (AGAL) [2]. Enzyme
replacement (ERT) is the only approved specific therapy for FD; it is well tolerated and safe [3].
The large phenotypic and genotypic spectrumof the disease poses several problems and the
cost-effectiveness of ERT is still debated, in particular for patients who have residual enzyme
activity [4]. In FD, about 40% of all missensemutations are associated with a biochemically
mildly damaged enzyme [5]. A therapy with sub-inhibitory concentrations of 1-deoxygalacto-
nojirimycin (DGJ) was first proposed by Suzuki and co-workers [6] and then tested in cells [7–
13], in mouse models of FD [14] [15] and in clinical trials [16] [17]. Such therapy is suitable
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only for patients carrying specificmutations (40%-60% of missensemutants tested in cell
based assays [11, 12]) and requires fine-tuning of the dosage regimen becauseDGJ is an inhibi-
tor of AGAL. The approach with small molecules for FD is promising, but DGJ is not yet the
ideal drug.Molecules that either substitute DGJ or act in synergy with it to enable reduced dos-
age of DGJ should be sought, in particular for mutants that do not respond to a monotherapy
with DGJ. Analogues of DGJ have been developed [18] [19]. A new family of arylthioureas
showed a better balance between the stabilizing effect, which is required, and the inhibitory
effect, which is detrimental [20]. However, these molecules bind the active site, as demon-
strated by x-ray crystallography, and enhance enzymatic activity only at micromolar concen-
tration, not dissimilarly from DGJ, when administered to eukaryotic cells expressing AGAL
mutants [20].
Ambroxol, a mucolytic agent used in the treatment of respiratory diseases, proved to be use-
ful in association with DGJ to rescue some AGAL mutants [21]. Its mechanism of action is not
clear since ambroxol is not specific for AGAL, but it is effective also on lysosomal beta-gluco-
cerebrosidase [22] and alpha-glucosidasemutants [21].
Discovery of chaperones directed against the active site is facilitated by focusing on mole-
cules with structural similarity to galactose, a natural product of AGAL. Conversely, the discov-
ery allosteric ligands, i.e. ligands that bind AGAL at sites outside the active site, is complicated
by the fact that they may not chemically resemble any known substrates or products.We per-
formed in silicomolecular docking (virtual screening) of over ten thousand low molecular
weight structurally diverse compounds previously filtered from ZINC database [23], by looking
for molecules that bind preferentially at a site different from the active site. Among the top
ranking hits we found one molecule, 2,6-dithiopurine (DTP). This molecule was chosen for
further studies since it has already passed some safety tests, is a known chemiopreventive agent
[24] [25] and it is safe when administered to mice [26]. DTP is able to stabilize AGAL against
thermal and urea-induced denaturation and is able to rescue a mutant that is not sensitive to
DGJ. It acts in vivo in synergy with galactose and with very low concentrations of DGJ.
Methods and Materials
Virtual screening
We selected a random subset of 9 millionmolecules (including FDA-approved drugs) from the
ZINC database [23] for performing the virtual screening calculations in this study. Molecular
docking calculations were carried out on the structure deposited in the PDB with the code
3S5Z [27] with the Leadfinder [28] docking program using default parameters. Protein struc-
ture 3S5Z contains 2 ligands: alpha-D-galactose (GLA) bound at the active site through D92,
D93, K168, E203, R227, D231 (GLA site) and beta-D-galactose (GAL) bound at a different site
through D255 and K374 (GAL site). Thus, two boxes (x, y, z dimensions 40 Å), centered on the
position occupied by either GLA or GAL, were set for docking. Using the global shape similar-
ity toolWEGA [29] alpha-D-galactose (the natural substrate of AGAL) was processed against
the selected compound library and those molecules with the highest values for similarity score,
ranging from 0.8 to 0.95, were selected for posterior docking studies. In total ten thousand pur-
chasable molecules obtained after filtering withWEGA were selected for docking.
Thermal unfolding
Thermal shift assay [30, 31] was adapted as described [32] using commercially available wt-
AGAL, Fabrazyme1 (Genzyme, Cambridge,MA). Melting profiles were recorded under differ-
ent conditions by thermal shift assay with the StepOne Real-Time PCR System (Applied Bio-
systems). The protein (0.5–1 mg/mL final concentration) was equilibrated in Na-Hepes 20
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mM, NaCl 150 mM, pH 7.4 with Sypro Orange 2.5X (Invitrogen Molecular Probes, lifetechnol-
ogies.com), either without ligands or in the presence of ligands (6 mMDTP, 0.040 mMDGJ
(SIGMA,Milan, Italy). The samples were distributed in 48-well PCR plates (0.025 mL in each
well), sealed and heated from 20 to 90° at 1°C/min with increments of 0.6°C. The excitation
wavelength of 490 nm and the emission wavelength of 575 nm, which are optimal for fluores-
cein, were adapted to detect Sypro Orange. Melting profiles of recombinant human phospho-
mannomutase2 were recorded similarly, the only exception was the presence of 1mMMgCl2
in the buffer. Phosphomannomutase 2 had been expressed and purified as described [33].
In order to verify the reversibility of the effect of DTP on Fabrazyme1, the enzyme equili-
brated in Na-Hepes 20 mM, NaCl 150 mM, pH 7.4 was incubated for 1 hour at 4°C in the pres-
ence of 6 mMDTP dissolved in DMSO, then the sample was dialysed by ultrafiltration (by
using Centrifugal ultrafiltration unit 15-mLMWCO 10 kDa,Merck-Millipore). A control
experiment was also conducted incubating the enzyme with DMSO and dialysing it. Each dia-
lysed sample was analysed by enzymatic assay (at pH 7.5) and by TSA (the experiment was
conducted either in the presence of 6 mMDTP or with only DMSO) as described above.
Urea-induced unfolding
The experiment was carried out with a method firstly describedby Kim et al [34] and adapted
as described [35]. In brief, Fabrazyme1 (0.32 mg/mL) was induced to unfold by urea in Hepes
buffer at pH 7.4, with or without DTP 6 mM, in a final volume of 0.028 mL. The enzyme was
incubated in the presence of urea concentrations ranging from 0 to 5 M. The samples were
incubated at 10°C overnight, then each sample was treated with the appropriate amount of
thermolysin necessary to obtain a 1:5 protease to protein ratio in the presence of CaCl2 (10
mM final concentration). After 1 min incubation at 37°C the reaction was stopped by the addi-
tion of EDTA (40 mM final concentration). The samples were separated by SDS-PAGE and
coloured by Coomassie Blue Staining, then undigested proteins (Fabrazyme1 and thermoly-
sin) were quantified with a ChemiDocXRS (Bio-Rad Laboratories, Hercules, CA-USA). Two
rectangular boxes were used to define specific protein bands, one for Fabrazyme1 and one for
thermolysin as shown in S1 File. The intensity of bands was corrected subtracting the appropri-
ate background (adjusted volumes), the ratio between the corrected values was calculated for
Fabrazyme1 and thermolysin in each lane and was plotted against urea concentration.
Transfection into COS-7 cells
COS-7cells were cultured in DMEM containing 10% FBS at 37°C and 5% CO2. The cells were
transfected with individual plasmids containing mutant AGAL-encoding ORF using the Lipo-
fectAMINE2000 cationic lipid reagent in suspension [36].
67.5 micrograms of plasmid DNA in 13.5 mL Opti-MEM (Invitrogen) were mixed with
0.135 mL LipofectAMINE2000 reagent (Invitrogen) and incubated for 30 min at room temper-
ature. COS-7 cells were harvested by trypsin treatment and resuspended in DMEM containing
10% FBS.
COS-7 in suspension (40.5 mL) were added to the transfectionmix solution, distributed
into 27 wells of six-well plates at 60% confluency and allowed to adhere for 5h.
The mediumwas substituted by fresh DMEM, 10% FBS, 1% DMSO (used to solubilize DTP
and ambroxol) (1 mL), and drugs were added either in monotherapy or in binary combination
as indicated in the specific figure legends. After 48 h incubation, the cells were washed in PBS
(5 times), scraped and harvested by centrifugation.Dry pellets were resuspended in 0.030 mL
of water and lysed by freeze-thawing.Three independent transfections were carried out for
A230T, C56Y, C63Y, two for the other mutants, E341D, A37T, P40S, M42T, M42V, S126C,
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C172G, R118C, Q280K, L300F, L310F and G360C.Water-soluble extracts were used for
enzyme assays or western blot. The Bradford colorimetric assay was used for protein quantifi-
cation [37] using the Bio-Rad Protein Assay with bovine serum albumin as standard.
Alpha-galactosidase assay
Tests on transfectedmutants were carried out as described in [36]. Briefly: cell lysates (1–2
microliters) were added to 38 microliters of AGAL assay buffer (sodium citrate 27 mM-sodium
phosphate dibasic 46 mM, 4-methylumbelliferyl-alpha-D-galactopyranoside 5 mM and N-ace-
tyl-D-galactosamine 100 mM, pH 4.5) and incubated for 0.5–1 h at 37°C. All chemicals were
obtained from Sigma. The reaction was stopped by adding 0.360 mL of 1 M sodium carbonate
buffer [10]. Fluorescence was detected using a fluorescence spectrophotometer (Cary Eclypse-
Varian) at 355 nm excitation and 460 nm emission.
A 4-methylumbelliferone standard curve ranging from 5 nM to 0.025 mMwas run in paral-
lel for conversion of fluorescence data to AGAL activity expressed as nmol/mg protein per
min.
In order to measure the enzymatic activity in the presence of DTP 6 mM a spectrophoto-
metric assay was run. Fabrazyme (1–2 microliters 0.25 mg/ml) were added to 0.038 mL of
AGAL assay buffer (4-Nitrophenyl α-D-galactopyranoside 17 mM in Hepes 40 mM pH 7.4)
and incubated for 3–15 min at 37°C. The reaction was stopped by adding 0.360 mL of 1 M
sodium carbonate and the absorbance at 405nm was measured. The assay was conducted in
the presence of DTP 6 mM (previously dissolved in DMSO) or DMSO.
Western blot analysis
Western blot analysis for the detection of AGAL was performed using rabbit polyclonal anti-
bodies (Abcam 70520) and HRP-coniugated anti-rabbit IgG antibody produced in goat (Bio-
Rad 1706515). After SDS-PAGE (15% acrylamide), proteins were transferred to a PVDFmem-
brane. The membrane was blocked with 5% (w/v) non-fat dried skimmedmilk in blot solution
at 4°C overnight, then treated with the primary antibody diluted in a blot solution 1:500 for 1
hour at room temperature. After washing, the detectionwas performed by using the Precision
Plus Protein™ (Bio-Rad). GAPDH was revealed with mouse monoclonal anti lapine GAPDH
(AbD seroTec (cat:4699–9555) 1:2000. All other chemicals were from Bio-Rad. Uncropped
images of the gels are provided as S1 File.
Deglycosylation
Deglycosylation of A230T expressed in COS7 cells (treated or untreated with DTP 6 mM)
(10 μg f each) was performed according to the producer's instructions. wt-AGAL was processed
at the same way as a control. Briefly, EDTA and SDS were added to the proteins (final concen-
trations were 20 mM and 0.1% respectively). The samples were then boiled for 5 min, immedi-
ately cooled before the addition of NP-40 to a final condition of 0.7% and N-Glycosidase F (0.5
unit) and incubated overnight at 37°C. A parallel experiment was conducted avoiding the
denaturation step (SDS and heating) before adding NP-40. The samples was analysed by west-
ern blotting as described elsewhere.
Bioinformatic and Statistical analysis
Standard deviations and p values (paired two-tailed Student's t-test) were obtained using
Microsoft Excel (Microsoft Office professional 2010).
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The effect of mutation on protein stability was predicted either running SDM on-line [38]
or runningMUPRO1.1[39] locally. Secondary structure was assigned with SEGNO [40].
Accessibility to solvent was calculated by SDM. Active site residues were identifiedwith Dro-
steP [41]. Molecular dynamics was run with Yasara program under default conditions for 50
nsec [42] and flexibility assessed as described [43]. Protein damaging scores based on sequence
conservationwere derived using PolyPhen-2 software [44] or Fabry_CEP [45].
Results
Molecular docking calculations were carried out on the AGAL structure deposited in the pdb
with the code 3S5Z [27]. In this model AGAL binds two ligands per chain: alpha-D-galactose
at the active site through D92, D93, K168, E203, R227 and D231 (GLA site) and beta-D-galac-
tose at a different site through D255 and K374 (GAL site). This structure offers a good target to
identifymolecules that have little inhibitory activity and/or act in synergy with drugs directed
against the active site. In proximity to the GAL site, we identified a hot-spot for binding that
will be referred to as the allosteric site. It comprises residues A37, R38, T39, P40, T41, M42,
E87, Y88 and does not overlap with the active site that is lined by W47, D92, D93, Y134, C142,
K168, D170, E203, L206, Y207, R227, D231, S297 (Fig 1). The allosteric site is different from
the GAL binding site.
We looked for molecules that bind the allosteric site with a high score, but bind the active
site with a very low score. Drug repositioning, which should always be considered as the first
choice when developing new therapies for rare diseases [46], could not be used because none of
the approved drugs tested (FDA database) bound specifically the allosteric site (results not
shown).
As a second choice we selectedDTP, which is not an approved drug, but is a good candidate
because it is safe when tested on human skin cells [25] and on mice [24] [26]. Even if the dock-
ing simulations started at GAL site DTP contacted the allosteric site. As a control we carried
out a simulation limiting the search to a box centred on the active site as described in the meth-
ods.We show the interactions of DTP with the allosteric site in Fig 1B, and the corresponding
energetic contributions in Fig 2A, the potential interactions of DTP with the active site (GLA
site) in Fig 1C and the corresponding energetic contributions in Fig 2B. Docking simulations
calculated a binding affinity at GLA’s binding site 52% lower (absolute value) than at the allo-
steric site (Fig 2). Scores calculatedwith Leadfinder [28] are reported as kcal/mol in Fig 2, but
are meant only for rank-ordering different docking poses of DTP and cannot provide accurate
binding energy predictions.
DTP does not inhibit AGAL (Fabrazyme1, Genzyme) when tested at 6 mM concentration
using 4-Nitrophenyl α-D-galactopyranoside 17 mM in Hepes 40 mM pH 7.4, whereas DGJ
blocks completely the enzyme (1% residual activity) at concentration as low as 0.001 mM.Ther-
mal shift assay was used to evaluate the ability of DTP (6mM) to stabilize wt-AGAL, (Fabra-
zyme1, Genzyme) in the presence or in the absence of DGJ. DTP is able to stabilize the
enzyme against thermal denaturation alone or in synergy with the iminosugar (Fig 3A). with-
out forming covalent bonds. To prove the reversibility of this stabilising effect, DTP (6 mM)
was incubated with enzyme and subsequently removed by dialysis before thermal shift assay.
Results are indicated in Fig 3B (filled squares DTP/DTP; open squares DMSO/DTP; filled cir-
cles; DTP/DMSO; open circles DMSO/DMSO) where the first word of the label corresponds to
the pretreatment and the second part corresponds to the presence of the compound during the
thermal scan. The specificity of effect of DTP was tested running thermal shift assay on phos-
phomannomutase2, an enzyme structurally and functionally unrelated to AGAL in the pres-
ence of DTP 6 mM or a positive control, glucose 1–6 bisphosphate 0.5 mM (S1 Fig).
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The stability of AGAL in the presence or in the absence of DTP was tested by unfolding
induced by a range of urea concentrations, followed by limited proteolysis. The enzyme unfolds
at 2.7 M urea in the absence of DTP, and at 3 M urea in the presence of DTP (Fig 4). A minor
band, which might represent a differently glycosylated form of AGAL, is observed in Fig 4. Its
intensity correlates with that of the major band (data not shown).
AGAL mutants were expressed transiently in COS-7 cells. We tested the effect of DTP on
the mutant A230T [47], which is non-responsive to DGJ [36], but eligible for PC therapy [48].
After transfection of A230T into COS-7 cells, specific bands were revealed by Western blot
(WB) and the total alpha-galactosidase activity was measured in cell extracts. In order to inter-
pret results it is worth remembering that AGAL is synthesized as a precursor of 50 kDa, but it
is converted into a mature form of 46 kDa. A detailed analysis of Ishii and co-workers [49]
demonstrated that when AGAL mutants are correctly processed into a 46 kDa form, they are
also transferred into lysosomes. In Fig 5A we show the migration of transfected wt-AGAL (90
±9 U/mg activity in the lysates) as a reference. A230T shows a faint band corresponding to the
precursor form of AGAL. This is not induced by the treatment with acknowledged PCs, DGJ,
Fig 1. The active site and the allosteric binding site in human lysosomal alpha-galactosidase. The structure of lysosomal alpha-
galactosidase is shown as a cartoon. In Panel A the active site (GLA site) is pinpointed by a blue sphere while the allosteric binding site is
pinpointed by a violet sphere. Residues involved in the 2,6-dithiopurine allosteric and alpha-galactose binding site respectively are shown
as sticks in Panel B or C respectively along with docked DTP. Predicted hydrogen bonds between DTP and AGAL within the allosteric
binding site are shown as yellow dashed lines in Panel B. Best ranked pose of DTP in the alpha-galactose binding site area is shown in
Panel C.
doi:10.1371/journal.pone.0165463.g001
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Fig 2. Energetic contributions to the binding of 2–6 dithiopurine to the allosteric site and the active site of human lysosomal
alpha-galctosidase. Depicted energetic contributions are: van der Waals interactions (dark blue), volume-based free energy of solvation
(green), hydrogen bonds (red), electrostatic energy (cyan), internal energy (pink), metal interactions (light yellow), energy of entropic
losses associated with ligand’s rotatable bonds (dark yellow), dihedral energy (light blue), internal energy penalty (light green) and total
predicted binding affinity (black). A) Decomposition for the allosteric site, and B), decomposition for the active site.
doi:10.1371/journal.pone.0165463.g002
Fig 3. 2–6 dithiopurine stabilizes human lysosomal alpha-galactosidase in thermal shift assay. Panel A.
Fabrazyme® (in Na-Hepes 20 mM, NaCl 150 mM, pH 7.4) was equilibrated in the presence of ligands dissolved in DMSO
20%: DGJ 1 microM (empty triangle) or 40 microM (empty circle); DTP 6 mM (empty diamond); DTP 6 mM plus DGJ 1
microM (filled circle); DTP 6 mM plus DGJ 40 microM (filled triangle). A control (with only DMSO) was also shown (x).
Panel B. Fabrazyme® (in Na-Hepes 20 mM, NaCl 150 mM, pH 7.4) was incubated in the presence of DTP 6 mM for 1 hour
at 4˚C then DTP was eliminated by dialysis. A control experiment was conducted by incubating the enzyme only with
DMSO. Both the aliquots of Fabrazyme® were analysed by thermal shift assay in the presence of DTP 6 mM or in the
presence of DMSO. Filled squares: DTP/DTP; open squares: DMSO/DTP; filled circles: DTP/DMSO; open circles:
DMSO/DMSO where the first word of the label corresponds to the pretreatment and the second part corresponds to the
presence of the compound during the thermal scan. The protein samples were heated from 20 to 90˚ at 1˚C/min in the
presence of Sypro Orange 2.5x. Data were shown as normalized curves.
doi:10.1371/journal.pone.0165463.g003
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galactose [50] or ambroxol [21], at the dosages commonly used to measure their chaperoning
effect on transfectedmutants, 0.020 mM, 100 mM or 0.040 mM respectively. However, DTP 6
mM promotes the maturation of A230T. Moreover, its effect is potentiated by galactose and
DGJ, even at very low concentration (0.001mM), but not by ambroxol (Fig 5A, 5B and 5C).
The lowest concentration at which DTP promotes A230T maturation is 2 mM (Fig 5D and
5E). The different bands visualised onWB represent different glycosylated forms, as demon-
strated by treatment of A230T or wt-AGAL with N-Glycosidase F Fig 5F.
We tested the effect of DTP 6 mM on furthermutants expressed in COS-7 cells: C56Y (Fig
6A), C63Y (Fig 6B) and E341D (Fig 6C). In these cases, enzymatic activity was not recovered
(Fig 6D), possibly because the proteins are not catalytically active, but increased protein pro-
cessing was detectable. C63Y and E341D are not responsive do DGJ [12, 13]. C56Y activity
increases in the presence of DGJ although it does not meet the criteria chosen Lukas et al [13]
to define responsiveness.
We tested four mutations affecting residues in the allosteric site, A37T, P40S, M42T, M42V.
None of these mutants responds to DTP (Fig 7). A37T [12], M42T [13] and M42V [8, 9, 12]
are responsive to 0.020 mMDGJ, whereas P40S is not [10, 11, 13]. This finding supports the
idea that DTP binds the allosteric site found in silico, although it does not prove it, because the
same molecule has no effect on mutations that do not affect the allosteric site. An example is
provided by S126C, C172G, and R118C which are not responsive to DGJ, [10–12, 51] (S2 Fig)
and by Q280K, L300F, L310F and G360C (S3 Fig), which are responsive to DGJ [12] [36].
Discussion
The catalytic domain of AGAL is formed by a TIM-barrel and the active site is located at the
carboxyterminal end of beta-strands, as expected [52].
We identified a different druggable pocket located at the opposite side of the TIM-barrel of
AGAL. Somemolecules resulting from our virtual screening bind better to the allosteric site
than to the active site. One of these molecules, a chemopreventive 2,6-dithiopurineDTP,
appeared particularly promising because it is actively transported into mammalian cells where
it accumulates at millimolar concentration [25] and it is safe [24] [26].
Fig 4. 2–6 dithiopurine protects human alpha-galactosidase against urea-induced unfolding. Fabrazyme® was
incubated in the presence of urea (from 0 to 5 M), with (B) or without (A) DTP 6 mM, at 10˚C over night, then each sample
was treated for 1 min at 37˚C with thermolysin (1:5 protease to protein ratio). Folded undigested proteins were visualized
by SDS-PAGE. The intensity of the bands was quantified and the relative intensity of major band of Fabrazyme® and
thermolysin in each lane was plotted against urea concentration (C).
doi:10.1371/journal.pone.0165463.g004
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DTP promotes the processing of some mutants of AGAL that are not responsive to DGJ
and in one case, A230T, enhances its activity in monotherapy as well as in synergy with DGJ or
galactose.
Not all missensemutations associated with FD are responsive to PC and we have not yet
found molecular features that are necessary and sufficient to determine responsiveness. Muta-
tions occurring at non conserved sites are generally less severe and responsive to PC, but there
are exceptions to this rule. The best example we encountered is A230T, a mutation occurring at
a non conserved site. A230 is exposed to solvent and exhibits moderate flexibility (Root mean
square fluctuation, RMSF, of alpha carbon 0.74 ±0.02 Å). A230 is not directly implicated in
catalysis, but it flanks D231, a proton donor that is essential for the hydrolysis of the substrate
and belongs to a short stretch in polyproline II conformation. Its mutation to Threonine is clas-
sified as mildly destabilizing by MUPRO [39] or SDM [38]. The position specific substitution
score, which measures the tolerability of the mutation in orthologous sequences and correlates
with responsiveness to DGJ, is benign [48]. A230T is classified as possibly damaging or benign
by HumDiv- and HumVar-trained PolyPhen-2 models respectively [44]. To summarize,
A230T is eligible for PC therapy and does respond to DTP, although it does not respond to
DGJ. Although DTP might be active only on a minority of AGAL missense mutations, we
Fig 5. 2–6 dithiopurine rescues mutant human alpha-galactosidase in monotherapy or in synergy. COS-7 cells
were cultured in conventional medium and transfected with plasmid containing A230T mutant. Cells were treated with:
DTP 6 mM, DGJ 1 microM, DGJ 20 microM, ambroxol 40 microM, ambroxol 40 microM plus DTP 6 mM, galactose 100
mM, galactose 100 mM plus DTP 6 mM, DGJ 1microM plus DTP 6 mM. All the molecules were dissolved in DMSO and an
appropriate control was realized. After 48 h incubation, the cells were scraped and lysed then water-soluble extracts were
analysed by western blotting (A and B) and enzyme assay (C). The effect of DTP 2 mM is shown in D and E. Cell extracts
were treated with N-Glycosidase F and then analysed by WB (F). Standard deviations is indicated by bars and differences
that are statistically significant are flagged by * when compared to the control with DMSO (p < 0.05:*; p < 0.01: **;
p < 0.001:***), are flagged by § when compared to DTP (p < 0.01:§§; p < 0.001:§§§).
doi:10.1371/journal.pone.0165463.g005
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Fig 6. 2–6 dithiopurine promotes processing of some mutant human alpha-galactosidase. COS-7 cells were
cultured in conventional medium and transfected with plasmid containing C56Y, C63Y and E341D mutants. Cells were
treated with: DTP 6 mM, DGJ 1 microM, DGJ 1 microM plus DTP 6 mM. All the molecules were dissolved in DMSO and
an appropriate control was realized. After 48 h incubation, the cells were scraped and lysed then water-soluble extracts
were analysed by western blotting (A, B and C) and enzyme assay (D). Standard deviations are indicated by bars.
doi:10.1371/journal.pone.0165463.g006
Fig 7. 2–6 dithiopurine has no effect on mutations affecting the allosteric site. COS-7 cells were cultured in conventional medium
and transfected with plasmid containing A37T, P40S, M42T, M42V mutants. Cells were treated with DTP 6 mM dissolved in DMSO and an
appropriate control was realized. After 48 h incubation, the cells were scraped and lysed then water-soluble extracts were analysed by
western blotting (A and B) and enzyme assay (C). Standard deviations are indicated by bars.
doi:10.1371/journal.pone.0165463.g007
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suggest that it should be tested in the cases that receive a positive score with Fabry_CEP [45],
but fail to respond to DGJ. We are aware that the interaction of DTP with AGAL, which occurs
in vitro only at high concentration, cannot exclude non specific off-target effects of the drug on
protein homeostasis. Derivatives of DTP obtained by techniques of lead optimization and
medicinal chemistrymight prove to be effective at lower doses and more specific.
Supporting Information
S1 Fig. 2–6 dithiopurine does not stabilizes human lysosomalphosphomannomutase2 in
thermal shift assay. Human Phosphomannomutase2 (in Na-Hepes 20 mM, NaCl 150 mM,
MgCl2 1mM pH 7.4) was equilibrated in the presence of ligands dissolved in DMSO 20%: DTP
6 mM (empty circle) and glucose 1, 6 bisphosphate (G16) 0.5 mM (filled squares) as a positive
control. A control (with only DMSO) was also shown (filled circles).
(TIF)
S2 Fig. 2–6 dithiopurine has no effect on somemutations that are not responsive to DGJ.
COS-7 cells were cultured in conventional medium and transfected with plasmid containing
R118C, S126C and C172Gmutants. Cells were treated with: DTP 6 mM, DGJ 1 microM, DGJ
1 microM plus DTP 6 mM. All the moleculeswere dissolved in DMSO and an appropriate con-
trol was realized. After 48 h incubation, the cells were scraped and lysed then water-soluble
extracts were analysed by western blotting (A, B and C) and enzyme assay (D). Standard devia-
tions are indicated by bars.
(TIF)
S3 Fig. 2–6 dithiopurine has no effect on somemutations that are responsive to DGJ. COS-
7 cells were cultured in conventional medium and transfected with plasmid containing L310F,
L300F, Q280K and G360Cmutants. Cells were treated with DTP 6 mM. All the molecules were
dissolved in DMSO and an appropriate control was realized. After 48 h incubation, the cells
were scraped and lysed then water-soluble extracts were analysed by western blotting (A, B)
and enzyme assay (C). Standard deviations are indicated by bars.
(TIF)
S1 File. Uncropped gels. Images are relative to gels shown in Figs 4, 5, 6 and 7.
(PDF)
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